Cancer
01 Jan 2013
Study of “NY-ESO-1 ISCOMATRIX” in Patients With High-Risk, Resected Melanoma
The purpose of this trial is to assess whether treatment with “NY-ESO-1 ISCOMATRIX” vaccine improves outcomes for people with Malignant Melanoma which has been removed, but is at high risk of relapse. Official Title Randomized, Double-Blind Phase II Trial of “NY-ESO-1 ISCOMATRIX” Vaccine and “ISCOMATRIX” Adjuvant Alone in Patients With…
Cancer
01 Jan 2013
A Safety Study of Two Intratumour Doses of Coxsackievirus Type A21 in Melanoma Patients.
The purpose of the study is to determine the safety and tolerability of two doses of Coxsackievirus A21, administered 48 hours apart into a superficial melanoma tumour. Injected and non-injected tumours will be observed regarding change in tumour size. Official Title A Phase I, Open Label, Cohort Study of Two…
Cancer
01 Jan 2013
Post-Operative Concurrent Chemo-Radiotherapy Versus Post-Operative Radiotherapy for Cancer of the Head and Neck
The primary objective of the trial is to determine, in patients who have undergone surgery with curative intent for high-risk cutaneous squamous cell carcinoma (CSCC) of the head and neck, whether there is a difference in time to loco-regional relapse between patients treated with post-operative concurrent chemo-radiotherapy ,consisting of Carboplatin,…
Cancer
01 Jan 2013
Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Cutaneous Squamous Cell Carcinoma In Situ
The purpose of this study is to determine whether the topical application of PEP005 is safe and effective for the treatment of cutaneous squamous cell carcinoma in situ (SCCIS, Bowen’s disease). Official Title Multi-Centre, Open-Label Study to Determine the Safety and Efficacy of PEP005 0.05% Topical Gel in Patients With…
Cancer
01 Jan 2013
Metvix PDT in Patients With “High Risk” Basal Cell Carcinoma
The variable “complete response” after one or two Metvix treatment cycles will be used as the basis for the justification of sample size. The following hypothesis will be tested: H0: Complete response rate of Metvix is less or equal to 65% versus the alternative hypothesis HA: Complete response rate…
Cancer
01 Jan 2013
Study to Compare the Efficacy and Safety of CC-5013 Vs. Placebo in Subjects With Metastatic Malignant Melanoma.
Subjects are randomized to one of two treatment arms. All subjects are screened for eligibility within 28 days prior to randomization. The study consists of a treatment phase and a follow-up phase. Subjects are treated in repeating 4 week cycles. Official Title Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Compare the…
Cancer
01 Jan 2013
A Study of LY573636 in Treating Patients With Malignant Melanoma
The primary objective of this study is to determine the objective response rate (complete and partial response) for patients who receive LY573636 after one prior systemic treatment for unresectable or metastatic melanoma. Official Title A Phase 2 Study of LY573636 Administered as an Intravenous Infusion on Day 1 of a…
Cancer
01 Jan 2013
Vaccine Therapy for Patients With Stage III Melanoma
This is a Phase 3 study in patients with melanoma that has spread to the lymph nodes (stage III), and who have had all of their cancer surgically removed. The purpose of this study is to evaluate the ability of the ‘CancerVax’ vaccine to prevent or slow the recurrence of…
Cancer
01 Jan 2013
OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
The purpose of this study is to determine if OSI-774 will improve overall survival of patients with incurable stage IIIB/IV non-small cell lung cancer compared to standard of care. OSI-774 is a new type of drug under evaluation called an epidermal growth factor receptor (EGFR). OSI-774 is an investigational drug…
